<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703508</url>
  </required_header>
  <id_info>
    <org_study_id>HM11153</org_study_id>
    <secondary_id>2U54HD034449</secondary_id>
    <nct_id>NCT00703508</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics of Metformin Action in PCOS</brief_title>
  <official_title>Pharmacogenetics of Metformin Action in PCOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The polycystic ovary syndrome is the major cause of infertility in the United States.
           Metformin has been shown to increase frequency of ovulations in PCOS, and is used in
           clinical practice to treat infertility, but some women with PCOS do not respond to
           metformin treatment.

        2. Knowing that a specific gene predicts the effect of metformin on ovulation would
           facilitate more efficient and effective treatment of infertility in PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The polycystic ovary syndrome (PCOS) affects approximately 6-10% of women of childbearing
      age, i.e., 3.5-5.5 million women in the United States. PCOS is the most common endocrine
      disturbance of young women and the major cause (75%) of anovulatory infertility in the United
      States. We hypothesize that women with the polycystic ovary syndrome (PCOS) who have the G/G
      genotype of single nucleotide polymorphism (SNP)_ rs8111699 in STK11 will exhibit a
      significantly greater response to metformin, in terms of ovulation, compared with women with
      either the C/G or C/C genotype. Specifically, we anticipate the frequency of ovulation
      (defined by number of ovulations/9 months/subject) to be at least 2-fold higher in women with
      the G/G STK11 genotype compared with women with either the C/G or C/C genotype.

      To test this hypothesis, we will obtain DNA for STK11 genotyping in 36 women with PCOS who
      are treated with metformin and carefully monitored for ovulation for 9 months. STK11 genotype
      status will be determined, and the ovulation rates in the G/G, G/C and C/C genotype groups
      will be compared with one another. Our goal is to identify the genes that predict or modify
      response to commonly prescribed medications that will allow physicians to better choose among
      existing therapies and individualize treatment. While metformin has been shown to increase
      ovulatory frequency in PCOS and is widely used in clinical practice to treat infertility, a
      substantial number of women either do not respond or are slow to respond to metformin
      treatment.

      Knowing that a specific STK11 genotype predicts the effect of metformin on ovulation would
      facilitate more efficient and effective treatment of infertility in PCOS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Responders/Non-responders for Each STK11 rs8111699 Genotype (C/G, C/C, G/G)</measure>
    <time_frame>9 months</time_frame>
    <description>Responders were defined as those that had a doubling of baseline ovulation rate estimated by self-report of menstrual history.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ovulation Rate Over Study Duration for STK11 Genotypes CC, CG and GG</measure>
    <time_frame>9 months</time_frame>
    <description>Ovulations were determined by measurement of daily urine pregnanediol-3-glucuronide or weekly progesterone levels over 6-9 months of study duration for each participant. The ovulation rate was calculated as the number of confirmed ovulation events per months of study participation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine in Which Genotype(s) Frequency of Ovulation Correlates With Improvement in Reduction in Total Testosterone and Insulin Sensitivity as Measured by the Matsuda Index.</measure>
    <time_frame>9 months</time_frame>
    <description>Bivariate fit (RSquare with P values) of ovulation rate post treatment by change in total testosterone and Matsuda Index for each of the 3 genotypes (G/G, C/G, C/C)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 500 mg tablet</intervention_name>
    <description>Metformin 500 mg tablets; two tablets every 12 hours for 9 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women between 18-45 years of age and BMI less than 42

          -  Diagnosed with PCOS as defined by the Rotterdam criteria, which is a combination of
             any two of the following three criteria: 1) chronic oligo- or amenorrhea (&lt;8 menstrual
             periods annually); 2) biochemical or clinical androgen excess; and 3) polycystic
             ovaries on ultrasonography -Normal thyroid function tests and serum prolactin; and
             exclusion of 21 alpha hydroxylase deficiency by a fasting 17 alpha hydroxyprogesterone
             less than 200 ng/dl -In acceptable health on the basis of interview, medical history,
             physical examination, and laboratory tests (CBC, SMA20,urinanalysis) -Able to provide
             signed, witnessed informed consent -Able to comply with study requirements

        Exclusion Criteria:

        -Diabetes mellitus by fasting glucose or OGTT, or clinically significant pulmonary,
        cardiac,renal,hepatic,neurologic,psychiatric,infectious,neoplastic and malignant disease
        (other than non-melanoma skin cancer) -Current use of oral contraceptives; use of fertility
        drugs within 6 months of study -Current or recent use (within 3 months prior to study
        entry) of metformin -Documented or suspected recent (within one year)history of drug abuse
        or alcoholism -Ingestion of any investigational drug within two months prior to study
        onset.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Nestler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Virginia General Clinical Research Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cheang KI, Bhavi Modi, Maria Shulleeta, William S. Evans, Lubna Pal, Jerome F. Strauss and John E. Nestler: Genetic Polymorphisms and Ovulatory Responsiveness to Metformin in Women with Polycystic Ovary Syndrome. Endo Reviews 36 (2): Supplement THR-109, Apr. 2015.</citation>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <results_first_submitted>January 5, 2017</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>55 subjects were enrolled, however some subjects failed to meet eligibility criteria resulting in 26 subjects initiating and completing all study phases.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
Metformin 500 mg tablet: Metformin 500 mg tablets; two tablets every 12 hours for 9 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
Metformin 500 mg tablet: Metformin 500 mg tablets; two tablets every 12 hours for 9 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Responders/Non-responders for Each STK11 rs8111699 Genotype (C/G, C/C, G/G)</title>
        <description>Responders were defined as those that had a doubling of baseline ovulation rate estimated by self-report of menstrual history.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G/G Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>C/G Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>C/C Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders/Non-responders for Each STK11 rs8111699 Genotype (C/G, C/C, G/G)</title>
          <description>Responders were defined as those that had a doubling of baseline ovulation rate estimated by self-report of menstrual history.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ovulation Rate Over Study Duration for STK11 Genotypes CC, CG and GG</title>
        <description>Ovulations were determined by measurement of daily urine pregnanediol-3-glucuronide or weekly progesterone levels over 6-9 months of study duration for each participant. The ovulation rate was calculated as the number of confirmed ovulation events per months of study participation.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>G/G Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>C/G Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>C/C Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Ovulation Rate Over Study Duration for STK11 Genotypes CC, CG and GG</title>
          <description>Ovulations were determined by measurement of daily urine pregnanediol-3-glucuronide or weekly progesterone levels over 6-9 months of study duration for each participant. The ovulation rate was calculated as the number of confirmed ovulation events per months of study participation.</description>
          <units>ovulations/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.310"/>
                    <measurement group_id="O2" value="0.36" spread="0.396"/>
                    <measurement group_id="O3" value="0.34" spread="0.336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine in Which Genotype(s) Frequency of Ovulation Correlates With Improvement in Reduction in Total Testosterone and Insulin Sensitivity as Measured by the Matsuda Index.</title>
        <description>Bivariate fit (RSquare with P values) of ovulation rate post treatment by change in total testosterone and Matsuda Index for each of the 3 genotypes (G/G, C/G, C/C)</description>
        <time_frame>9 months</time_frame>
        <population>Individuals that were lost to follow up had missing data on testosterone and OGTT (oral glucose tolerance testing) for Matsuda index.</population>
        <group_list>
          <group group_id="O1">
            <title>G/G Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>C/G Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
          <group group_id="O3">
            <title>C/C Genotype</title>
            <description>Metformin tablet, 500 mg per tablet, 2 tablets every 12 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Determine in Which Genotype(s) Frequency of Ovulation Correlates With Improvement in Reduction in Total Testosterone and Insulin Sensitivity as Measured by the Matsuda Index.</title>
          <description>Bivariate fit (RSquare with P values) of ovulation rate post treatment by change in total testosterone and Matsuda Index for each of the 3 genotypes (G/G, C/G, C/C)</description>
          <population>Individuals that were lost to follow up had missing data on testosterone and OGTT (oral glucose tolerance testing) for Matsuda index.</population>
          <units>Correlation coefficient (r^2)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ovulation rate vs Testosterone post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.138956"/>
                    <measurement group_id="O2" value="0.035449"/>
                    <measurement group_id="O3" value="0.049263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovulation rate vs Matsuda Index post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27144"/>
                    <measurement group_id="O2" value="0.01918"/>
                    <measurement group_id="O3" value="0.132059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0234</p_value>
            <p_value_desc>Ovulation rate vs Testosterone post-treatment, threshold for statistical significance = p&lt;0.05</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0740</p_value>
            <p_value_desc>Ovulation rate vs Testosterone post-treatment, threshold for statistical significance = p&lt;0.05</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4698</p_value>
            <p_value_desc>Ovulation rate vs Testosterone post-treatment, threshold for statistical significance = p&lt;0.05</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1180</p_value>
            <p_value_desc>Ovulation rate vs Matsuda Index post-treatment, threshold for statistical significance = p &lt; 0.05.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0311</p_value>
            <p_value_desc>Ovulation rate vs Matsuda Index post-treatment, threshold for statistical significance = p &lt; 0.05.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1586</p_value>
            <p_value_desc>Ovulation rate vs Matsuda Index post-treatment, threshold for statistical significance = p &lt; 0.05.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For entire 9 months of study plus 30 days after study completion</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
Metformin 500 mg tablet: Metformin 500 mg tablets; two tablets every 12 hours for 9 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Interpretations of our findings are limited by our small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kai Cheang</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>(804) 828-2257</phone>
      <email>kicheang@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

